Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.

This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This study found that dutasteride is not associated with an increased risk of osteoporosis or fractures in older men compared to finasteride, suggesting dutasteride does not adversely affect bone health.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

This study reported a significant association between severe teenage acne and an increased risk of melanoma, potentially linked to androgen levels, though causation cannot be confirmed.

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.

In this randomized trial of Iranian men with moderate to severe androgenetic alopecia, researchers found that both finasteride and dutasteride improved hair density over 24 weeks, with dutasteride showing stronger PSA reduction but similar safety to finasteride.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

Both treatment combinations improved hair growth similarly and were safe.

This article discusses how 5-alpha-reductase inhibitors like finasteride and dutasteride are used to treat androgenetic alopecia, while highlighting the ongoing debate over their potential side effects, including sexual dysfunction and psychological issues.

This integrative literature review suggests that phytotherapeutic products, like Saw palmetto and Green tea, could serve as viable alternatives to current medications like finasteride for treating androgenetic alopecia, potentially offering fewer side effects.

This review found that both finasteride and dutasteride are effective for treating hair loss in men with androgenetic alopecia, with dutasteride showing higher efficacy, but noted unclear clinical significance regarding potential negative impacts on reproduction, including possible sexual dysfunction and effects on spermatogenesis.

This source highlights topical minoxidil as the first-line treatment for androgenetic alopecia in both genders and finasteride for men, while also identifying dutasteride, low-dose oral minoxidil, and topical finasteride as promising future options.

In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.